$LLY Is launching its acute migraine drug Reyvow (lasmiditan) now that it has received DEA scheduling - class V, the lowest potential for abuse.https://www.prnewswire.com/news-releases/lillys-reyvow-lasmiditan-c-v-the-first-and-only-medicine-in-a-new-class-of-acute-treatment-for-migraine-ditan-now-available-for-prescription-300996903.html …
“A benefit of ditans, like Lilly’s Reyvow, is that they are not associated with vasoconstriction, which is seen with triptans, making the older drugs contraindicated in patients with cardiovascular disease.” (Subscription required)https://scrip.pharmaintelligence.informa.com/SC141524/Market-Snapshot-Three-Acute-Migraine-Launches-Are-First-In-Over-20-Years …